TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07432958: A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

Sponsor: Appello Pharmaceuticals, Inc. · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 150 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,987,600

Rescue Site Savings

+$1,978,800

Unlock Full NCT07432958 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07432958 Rescue Dossier →